-
Case challenge| 64-year-old man, what is the cause of back pain after modified radical mastectomy for breast cancer
Time of Update: 2023-01-07
Present medical history: the patient complained of a right breast mass for 4 months 7 years ago, and after hollow core needle biopsy, the pathology showed estrogen receptor (ER) positive and HER2-negative breast cancer.
-
Antitumor peptide immune checkpoint inhibitors
Time of Update: 2022-11-15
Inhalation is not equal to nasal spray, what is the difference between the two vaccination methods?【Route of administration】Gastrointestinal administration and lung administrationAnalysis of the latest patent layout of key PI3K inhibitorsOrphan Drug Development: Shelter the World for Patients with Rare Diseases【Route of administration inventory】Ocular administrationClick "Read Original" to keep abreast of industry trendsCTLA-4 or CTLA4 (cytotoxic T lymphocyte-associated protein 4), also known as CD152, is a protein receptor that acts as an immune checkpoint and downregulates the immune response.
-
ESMO Strikes Directly at the First Prospective Study: An Exploration of the Mechanism of Oshitinib Resistance
Time of Update: 2022-10-03
Details are as follows:Professor Zofia Piotrowska1 backgroundThird-generation EGFR TKI ositinib is the preferred first-line treatment for patients with advanced NSCLC with EGFR mutation.
Details are as follows:Professor Zofia Piotrowska1 backgroundThird-generation EGFR TKI ositinib is the preferred first-line treatment for patients with advanced NSCLC with EGFR mutation.
-
Daiichi Sankyo/AstraZeneca's Enhertu receives FDA breakthrough therapy designation for breast cancer
Time of Update: 2022-05-12
On April 27, AstraZeneca and Daiichi Sankyo jointly announced that the HER2 ADC drug Enhertu has been granted Breakthrough Therapy Designation (BTD) by the FDA for relapse or progression within six months of adjuvant therapy after receiving at least one prior systemic therapy Patients with unresectable or metastatic breast cancer with low HER2 expression (IHC1+orIHC2+/ISH-negative) .
-
Johns Hopkins: Cerebrospinal fluid can identify aggressive brain tumors in children
Time of Update: 2022-04-27
"We believe this is the first comprehensive, integrative molecular analysis of cerebrospinal fluid from patients with medulloblastoma," said the study's senior author Ranjan Perera, PhD, of the Johns Hopkins All Children's University in St.
-
Cancer patients should never use probiotics indiscriminately
Time of Update: 2022-01-24
The researchers found that melanoma patients did not respond equally to immune checkpoint inhibitor (ICI) treatment after consuming dietary fiber and probiotics, with high dietary fiber intake associated with significant improvement without progression compared with use of probiotics survival related .
-
The Triple Therapy of Gastric Cancer "Nature" Paper
Time of Update: 2022-01-01
A paper The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer published in Nature showed that the combination of immunotherapy with chemotherapy and targeted drugs is expected to improve the transformation of patients with HER2-positive gastric cancer.
-
CDE releases 2 technical guidelines for clinical trials involving weight control and advanced prostate cancer
Time of Update: 2021-12-29
Attachment: Notice on Technical Guidelines for Clinical Trials of Weight Control Drugs Regarding the Public Solicitation of "Technical Guidelines for Endpoints for Advanced Prostate Cancer Clinical Trials (Draft for Comment)" Prostate cancer is a common urinary system malignant tumor, which is unique compared to other solid tumors The characteristics of the disease, such as different disease stages according to the sensitivity to androgen deprivation treatment and whether it has metastasis, high incidence of bone metastasis and serum biomarker PSA, etc.
-
JGH: Tumor burden score can be used as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization
Time of Update: 2021-12-27
Baseline demographic data and clinical variables of all patients, such as the etiology of liver disease, laboratory data, tumor burden (number) and tumor burden (number and size of tumors, vascular infiltration and TBS), liver function reserve, performance status and The Barcelona Clinic Liver Cancer (BCLC) staging is recorded at the time of diagnosis .
-
BMJ: Premenopausal non-malignant hysterectomy patients should be cautious about bilateral salpingo-ovarian resection
Time of Update: 2021-12-26
Guidelines for the Prevention of Ovarian Cancer Recently, researchers have investigated the impact of bilateral salpingo-oophorectomy compared with ovarian sparing in patients undergoing hysterectomy for non-malignant diseases on the risk of subsequent death, and the impact of surgical age on the prognosis .
-
100% objective relief
Time of Update: 2021-12-05
In May of this year, the MD Anderson Cancer Center of the University of Texas in the United States published the latest research results in Clinical Cancer Research of the American Association for Cancer Research, showing that cytokine-activated donor cord blood-derived natural killer (cbNK) cells combine to target CD16a and The CD30 research bispecific antibody AFM13 has strong anti-tumor activity against CD30+ lymphoma cells .
-
Clinical Lung Cancer: The efficacy and safety of pemetrexed +/- anti-VEGF maintenance in patients with advanced non-squamous non-small cell lung cancer (NSQ-NSCLC) after chemotherapy
Time of Update: 2021-11-13
Subgroup analysisSubgroup analysisThe most common TEAEs of any grade in patients in the pemetrexed maintenance group ( incidence ≥20% during the entire treatment cycle ) were nausea, fatigue, vomiting, anemia, neutropenia, constipation, decreased appetite, fatigue, Peripheral edema and insomnia .
-
Protein LAG-3 is expected to predict which cancer patients will respond to immune checkpoint inhibitors
Time of Update: 2021-09-11
In a new study, researchers from the Memorial Sloan-Kettering Cancer Center in the United States found that specific patterns or "signatures" of markers on the surface of immune cells in the blood may be the result of immune checkpoint immunotherapy.
-
The report shows that the incidence of adult brain tumors is declining, but the 5-year survival rate is still very low
Time of Update: 2021-09-04
Glioblastoma accounts for 49% of all malignant brain cancers in the United StatesThe incidence of non-malignant tumors (mainly affecting women and blacks) is slowly increasing, which may be due to improved case detection and increased awareness .
-
Br J Cancer: Research on Non-invasive Diagnosis Strategy of Gastric Cancer Based on the Features of Blood Transcriptomics
Time of Update: 2021-07-31
The study mainly identified a new 5-gene biomarker evaluation system for non-invasive diagnosis of GC, which may be used as a potential diagnostic tool for early detection of the disease .
